Alpha Tau Medical (NASDAQ:DRTS) Stock Jumps 5.2% – Here’s What Happened

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report)’s share price rose 5.2% on Friday. The company traded as high as $11.82 and last traded at $11.90. Approximately 82,989 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 587,964 shares. The stock had previously closed at $11.31.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on DRTS shares. Barclays boosted their price objective on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, September 3rd. Piper Sandler raised shares of Alpha Tau Medical from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $8.00 to $22.00 in a research report on Wednesday, November 11th. Wall Street Zen raised Alpha Tau Medical from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Thursday, October 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Alpha Tau Medical in a research note on Tuesday, November 17th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.20.

Read Our Latest Analysis on Alpha Tau Medical

Alpha Tau Medical Trading Up 3.9%

The firm has a 50-day moving average of $13.79 and a 200 day moving average of $11.03. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.30 and a beta of 1.28.

Hedge Funds Weigh In On Alpha Tau Medical

Large investors have recently made changes to their positions in the business. Everhart Financial Group Inc. acquired a new stake in Alpha Tau Medical during the 2nd quarter valued at $126,000. Principal Financial Group Inc. purchased a new position in Alpha Tau Medical during the 1st quarter valued at about $132,000. Finally, Renaissance Technologies LLC purchased a new position in Alpha Tau Medical during the 1st quarter valued at about $286,000. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.

Recommended Stories

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.